The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center

Background: Although there is evidence that the CYP3A4*22 variant should be considered in tacrolimus dosing in renal transplantation, its impact beyond tacrolimus dose requirements remains controversial.Methods: In a cohort of 121 kidney transplant recipients, we analyzed the CYP3A4*1B, CYP3A4*22, a...

Full description

Bibliographic Details
Main Authors: Emaad Abdel-Kahaar, Stefan Winter, Roman Tremmel, Elke Schaeffeler, Christoph J. Olbricht, Eberhard Wieland, Matthias Schwab, Maria Shipkova, Simon U. Jaeger
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Genetics
Subjects:
tacrolimus
renal transplantation
pharmacogenetics
CYP3A5
CYP3A4*22
ABCB1
Online Access:https://www.frontiersin.org/article/10.3389/fgene.2019.00871/full

Internet

https://www.frontiersin.org/article/10.3389/fgene.2019.00871/full

Similar Items